575 related articles for article (PubMed ID: 32685019)
1. Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.
Lee J; You JH; Shin D; Roh JL
Theranostics; 2020; 10(17):7775-7786. PubMed ID: 32685019
[No Abstract] [Full Text] [Related]
2. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer.
Shin D; Lee J; You JH; Kim D; Roh JL
Redox Biol; 2020 Feb; 30():101418. PubMed ID: 31931284
[TBL] [Abstract][Full Text] [Related]
3. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
5. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
Kim EH; Shin D; Lee J; Jung AR; Roh JL
Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
7. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition.
You JH; Lee J; Roh JL
Cancer Lett; 2021 Jun; 507():40-54. PubMed ID: 33741422
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of AEBP1 predisposes cisplatin-resistant oral cancer cells to ferroptosis.
Zhou Q; Wang X; Zhang Y; Wang L; Chen Z
BMC Oral Health; 2022 Nov; 22(1):478. PubMed ID: 36352396
[TBL] [Abstract][Full Text] [Related]
10. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells.
You JH; Lee J; Roh JL
J Exp Clin Cancer Res; 2021 Nov; 40(1):350. PubMed ID: 34749765
[TBL] [Abstract][Full Text] [Related]
11. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
[TBL] [Abstract][Full Text] [Related]
12. Salvia miltiorrhiza Bge. processed with porcine cardiac blood inhibited GLRX5-mediated ferroptosis alleviating cerebral ischemia-reperfusion injury.
Zhou S; Wang Z; Wang T; Peng C; Zhang J; Liu C; Xu J; Zhang Y; Zhang L; Luo L; Yan X
Phytomedicine; 2024 Jul; 129():155622. PubMed ID: 38677272
[TBL] [Abstract][Full Text] [Related]
13. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic reprogramming of epithelial-mesenchymal transition promotes ferroptosis of head and neck cancer.
Lee J; You JH; Kim MS; Roh JL
Redox Biol; 2020 Oct; 37():101697. PubMed ID: 32896720
[TBL] [Abstract][Full Text] [Related]
15. Poly(rC)-binding protein 1 represses ferritinophagy-mediated ferroptosis in head and neck cancer.
Lee J; You JH; Roh JL
Redox Biol; 2022 May; 51():102276. PubMed ID: 35290903
[TBL] [Abstract][Full Text] [Related]
16. Promotion of ferroptosis in head and neck cancer with divalent metal transporter 1 inhibition or salinomycin.
Lee J; Roh JL
Hum Cell; 2023 May; 36(3):1090-1098. PubMed ID: 36890422
[TBL] [Abstract][Full Text] [Related]
17. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
18. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
19. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
20. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
